Study to Determine the Efficacy&Safety of ARV-1801(ACG-701) for the Treatment of Cystic Fibrosis Pulmonary Exacerbations

Cystic Fibrosis Clinical Trial

— REPRIEVE  

Official title:

A Phase 2, Randomized, DB, Placebo-controlled Study to Determine the Efficacy, Safety and PK Profile of ARV-1801 in Combination With Optimized Background Therapy for the Treatment of Pulmonary Exacerbations in Patients With Cystic Fibrosis

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT05641298
• Other study ID #: ACG-701-101
• Status: Withdrawn
• Phase: Phase 2
• Start date: February 10, 2023
• Est. completion date: September 2023

Study information

• Verified date: February 2023
• Source: Aceragen
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will evaluate the efficacy and safety of an oral ARV-1801(ACG-701) plus optimized background therapy (OBT) compared to oral placebo plus OBT, each administered for 14 days, in the treatment of participants with Cystic Fibrosis-related pulmonary exacerbations (PEx).

Description:

This is a Phase 2, randomized, double-blind, multicenter study designed to evaluate the efficacy and safety of an oral ARV-1801/ACG-701 plus OBT compared to oral placebo plus OBT, each administered for 14 days, in the treatment of participants with CF-related PEx.

Participants who provide informed consent (plus informed assent, if applicable) and meet all study eligibility criteria will be enrolled in the study and randomized via an interactive response technology (IRT) in a 1:1 ratio to receive ARV-1801/ACG-701 or placebo in addition to OBT for 14 days. A participant may be hospitalized (inpatient) or treated as an outpatient. If admitted to the hospital for initial treatment, the participant may be discharged at the Investigator's discretion to complete study therapy as an outpatient. The target study population will comprise 80 participants.

The duration of participation in the study for an individual participant will be approximately 28 days and will involve up to 5 clinic visits as well as the requirement to complete an electronic symptom questionnaire every day for the duration of the study. Participation will include a Screening period of up to 24 hours prior to the first dose of study drug (Day 1), a 14 day treatment course of study drug, a Day 7 visit (±1 day), an end of treatment (EOT) visit (day of last dose of study drug +3 days), and end of study (EOS) visit on Day 28 (+3 days).

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: September 2023
• Est. primary completion date: September 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 12 Years and older

Eligibility

Inclusion Criteria:

1. Males and females of 12 years of age and older

2. Participants must have a confirmed diagnosis of Cystic Fibrosis with a diagnosis of an acute pulmonary exacerbation as defined as:

1. Deterioration in 3 or more of the following symptoms for at least 48 hrs (cough, sputum volume and/or consistency, sputum purulence, breathlessness and/or exercise tolerance, fatigue and/or malaise, or hemoptysis) And

2. a clinician determines that a change in CF treatment is required

3. Participants must have a CFRSD-CRISS score of >/= 35

4. Participants must have a moderate or Severe Patient Global Impression of Severity

5. Participants must have a negative pregnancy test and agree to use a highly effective method of contraception during the study and 30 days after last dose

6. Participants must agree not to smoke during any part of the clinical trial

7. Participants must voluntarily sign the informed consent for the study

Exclusion Criteria:

1. Participants cannot have any changes in any antimicrobial, bronchodilator, anti-inflammatory, CFTR modulator or corticosteroid medications from 28 - 3 days prior to the Screening visit.

2. Participants cannot be receiving treatment for non-tuberculosis mycobacteria and/or Aspergillus infection.

3. History of hypersensitivity or allergic reaction to sodium fusidate, fusidic acid (Fucidin®) or its excipients.

4. Abnormal laboratory findings or other findings or medical history at Screening that, in the Investigator's opinion, would compromise the safety of the participant or the quality of the study data.

5. The use of an investigational drug or device (ie, a drug or device without the FDA approved indication) within 30 days prior to the Screening visit

6. Known severe renal impairment, as indicated by estimated creatinine clearance (CrCl) <30 mL/min (by Cockcroft-Gault calculation).

7. Evidence of significant liver disease: ALT >3×ULN, or direct bilirubin >ULN, or total bilirubin >1.5 mg/dL; known cirrhosis with decompensation (ie, Child-Pugh Class B or C disease).

8. Known hepatitis C virus (HCV) or infection and currently receiving HCV-specific antiviral therapy. HCV infection alone, and in the absence of decompensated liver disease, is not exclusionary.

9. Neutropenia (absolute neutrophil count <500/µL); thrombocytopenia (<60,000 platelets/mm3).

10. Known human immunodeficiency virus (HIV) infection and currently receiving antiretroviral therapy, or current CD4 count =200 cells/mm3 (documented within 3 months prior to enrollment); if CD4 count is unknown, participant may not enroll.

11. Changes to or initiation of immunosuppressant agents (ie, prednisone [=15mg/day], cyclosporine, tumor necrosis factor alpha [TNFa] antagonist) within 30 days of study medication administration through the EOS visit.

12. Malignancy requiring ongoing cytotoxic chemotherapy or radiation therapy.

13. Requires concomitant treatment with (washout period prior to randomization allowed):

• OATP1B1 and OATP1B3 substrates (eg, HMG-CoA reductase inhibitors [statins])

• CYP2C8 substrates, namely glitazones (eg, repaglinide)

• CYP3A4 inducers (eg, dexamethasone, phenytoin, carbamazepine, rifampin, phenobarbital, nafcillin)

• Moderate/strong CYP3A4 inhibitors (eg, azole antifungals, erythromycin, clarithromycin)

• P-gp substrates with narrow therapeutic windows (eg, digoxin and colchicine)

14. Prior treatment with a CYP3A4 inducer (such as lumacaftor, dexamethasone, phenytoin, carbamazepine, rifampin, phenobarbital and nafcillin) within 7 days prior to enrollment.

15. Dietary use of large amounts of grapefruit juice and/or Seville oranges or other products containing these fruits (eg, grapefruit juice or marmalade) during the study.

16. Participant requiring warfarin therapy.

17. Seizure disorder requiring current therapy with an anticonvulsant.

18. Female participant who is pregnant or lactating.

19. History of /current chronic alcohol consumption and/or drug abuse (including cannabis use).

20. Any study personnel or their immediate dependents, family, or household members.

Related Conditions & MeSH terms

• Cystic Fibrosis
• Cystic Fibrosis Pulmonary Exacerbation
• Fibrosis
• Pulmonary Fibrosis

Intervention

Drug:
• Sodium Fusidate
Tablets
• Placebo
Tablets

Locations

Country	Name	City	State
United States	University of Michigan, Michigan Medicine	Ann Arbor	Michigan
United States	Johns Hopkins University	Baltimore	Maryland
United States	Medical University of South Carolina	Charleston	South Carolina
United States	Cystic Fibrosis Center of Chicago	Chicago	Illinois
United States	Rainbow Babies and Children's Hospital/Cleveland Medical Center	Cleveland	Ohio
United States	Cook Children's Health Care System	Fort Worth	Texas
United States	University of Florida	Gainesville	Florida
United States	New York Medical College	Hawthorne	New York
United States	Riley Hospital for Children	Indianapolis	Indiana
United States	University of Kansas Medical Center	Kansas City	Kansas
United States	University Of Louisville	Louisville	Kentucky
United States	Gunnar H. Esiason Adult Cystic Fibrosis Center	Morristown	New Jersey
United States	Vanderbilt University Medical Center	Nashville	Tennessee
United States	Cystic Fibrosis Center of Chicago	Northfield	Illinois
United States	University of Oklahoma Health Sciences Center	Oklahoma City	Oklahoma
United States	UNMC-Nebraska CF Pediatric Center	Omaha	Nebraska
United States	Central Florida Pulmonary Group	Orlando	Florida
United States	Nemours Children's Health - Pensacola	Pensacola	Florida
United States	University of Pittsburgh Medical Center	Pittsburgh	Pennsylvania
United States	Maine Medical Center	Portland	Maine
United States	University of Rochester Medical Center Strong Memorial	Rochester	New York
United States	Washington University School of Medicine	Saint Louis	Missouri
United States	Johns Hopkins All Children's Hospital	Saint Petersburg	Florida
United States	Providence Medical Research Center	Spokane	Washington
United States	The University of Health Science Center at Tyler	Tyler	Texas

Sponsors (1)

Lead Sponsor	Collaborator
Aceragen

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Desirability in outcome ranking (DOOR)	To demonstrate that the addition of oral ARV-1801(ACG-701) to OBT is superior to placebo plus OBT based on DOOR in cystic fibrosis pulmonary exacerbations.	Day 7